Compositions and methods for the detection diagnosis and therapy of hematological malignancies
Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, B cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and T cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal. Also disclosed are compositions and methods for use in the identification of cells and biological samples containing one or more hematological malignancy-related compositions, and methods for the detection and diagnosis of such diseases and affected cell types. Also disclosed are diagnostic and therapeutic kits, as well as methods for the diagnosis, therapy and/or prevention of variety of leukemias and lymphomas.
1. A method for treating chronic lymphocytic leukemia (CLL) in a mammalian subject wherein a B-cell from said subject overexpresses SEQ ID NO:4 comprising administering to said subject an effective amount of an isolated monoclonal antibody that specifically binds to a polypeptide comprising the sequence set forth in SEQ ID NO: 4 wherein said monoclonal antibody has a binding constant for SEQ ID NO:4 that exceeds 10 3 L/mol.
2. The method of claim 1 , wherein said antibody is a humanized antibody.
3. The method of claim 1 , wherein said antibody is a chimeric antibody.
4. The method of claim 1 , wherein said antibody is a Fab fragment.
5. The method of claim 1 , wherein said antibody is a Fv fragment.
6. The method of claim 1 , wherein said antibody is a scFv.
7. The method of claim 1 , wherein said antibody further comprises a therapeutic moiety.
8. The method of claim 7 , wherein the therapeutic moiety is a radionuclide.
9. The method of claim 8 , wherein the radionuclide is a member selected from the group consisting of; 90 Y, 123 I, 125 I, 131 I, 186 Re, 211 At, and 212 Bi.
10. The method of claim 8 , wherein the mammalian subject is a human.
11. The method of claim 1 , wherein administration is intravenous.
12. The method of claim 1 , wherein the monoclonal antibody is not a bi-specific antibody.